Sayan Mondal

This inventor holds 26 USPTO granted patents and 10 published patent applications and 8 EPO patents, primarily in Cancer Therapeutics. Top assignees: Nimbus Lakshmi, Inc., Nimbus Lakshimi, Inc., Ajax Therapeutics, Inc.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sayan Mondal. Retrieved from https://idiyas.com/inventor/sayan-mondal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 10)

% Patents Active = 100.0

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Newark, NJ (US) (2023)
New York, NY (US) (2018 - 2024)

Company Filing History:

Nimbus Lakshimi, Inc.

patents

5 out of 5

Ajax Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

patents

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Cyclic Compounds

JAK2 Inhibitors

TYK2 Inhibitors

Drug Discovery

Cancer Treatment

Heterocyclic Compounds

Compound Solubility

Computational Methods

Pharmaceutical Compositions

Kinase Inhibitors

Alternative Cores

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715876 - Cyclic compounds and methods of using same (2026-08-25),

2. 12686688 - Heterocyclic pericondensed CDC7 kinase inhibitors for the treatment of cancer (2026-07-21),

3. 12275717 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2025-04-14),

4. 12221453 - Substituted pyrazolo[5',1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors (2025-02-11),

5. 12162881 - Forms and compositions of inhibitors of JAK2 (2024-12-10),

6. 12043632 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2024-07-23),

7. 11970494 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2024-04-30),

8. 11710543 - Methods for predicting an active set of compounds having alternative cores, and drug discovery methods involving the same (2023-07-25),

9. 11691963 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2023-07-04),

10. 11434240 - TYK2 inhibitors and uses thereof (2022-09-06),

11. 11414431 - Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors (2022-08-16),

12. 11396508 - TYK2 inhibitors and uses thereof (2022-07-26),

13. 11220508 - TYK2 inhibitors and uses thereof (2022-01-11),

14. 11046698 - TYK2 inhibitors and uses thereof (2021-06-29),

15. 10793574 - TYK2 inhibitors and uses thereof (2020-10-06),

Title: Unveiling the Innovations of Inventor Sayan Mondal

Introduction:

In the vibrant landscape of invention and innovation, New York-based inventor Sayan Mondal stands out with his remarkable contributions to the field. With a total of 20 patents under his belt, Sayan Mondal has been at the forefront of pioneering developments in various scientific domains.

Latest Patents:

One of Sayan Mondal's latest patents includes the groundbreaking work on "6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors." This patent introduces novel compounds and compositions that exhibit efficacy in inhibiting JAK2, opening new possibilities in the realm of drug discovery and therapeutic interventions. Additionally, Sayan Mondal has made significant strides in predictive methodologies for identifying active compounds that bind to biomolecular targets, as evidenced by the patent on "Methods for predicting an active set of compounds having alternative cores."

Career Highlights:

Throughout his career, Sayan Mondal has made significant contributions while working at prominent companies such as Nimbus Lakshmi, Inc. and Nimbus Lakshimi, Inc. His innovative spirit and dedication to scientific advancement have propelled him to the forefront of the industry, earning him recognition for his groundbreaking work in the field of pharmaceuticals and drug discovery.

Collaborations:

Sayan Mondal's collaborative efforts have been instrumental in driving innovation forward. He has worked alongside esteemed colleagues such as Jeremy Robert Greenwood and Craig E Masse, leveraging collective expertise and insights to push the boundaries of scientific exploration and discovery.

Conclusion:

Inventor Sayan Mondal's relentless pursuit of innovation and commitment to scientific excellence have positioned him as a trailblazer in the realm of inventions and patents. His groundbreaking work continues to shape the landscape of drug discovery and predictive methodologies, heralding a new era of possibilities in the field.

Profile summary based on public USPTO records.